Eisai Co., Ltd. (ESALF)
OTCMKTS
· Delayed Price · Currency is USD
29.31
0.00 (0.00%)
Jul 2, 2025, 4:00 PM EDT
Eisai Revenue
In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B JPY with 6.42% growth. Eisai had revenue of 188.24B in the quarter ending March 31, 2025, a decrease of -1.19%.
Revenue
789.40B JPY
Revenue Growth
+6.42%
P/S Ratio
1.53
Revenue / Employee
72.31M JPY
Employees
10,917
Market Cap
8.06B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 84.04M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Eisai News
- 24 days ago - Eisai: Leqembi Approved In EU (Rating Downgrade) - Seeking Alpha
- 7 weeks ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Eisai Co., Ltd. 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 7 weeks ago - Eisai GAAP EPS of ¥163.76, revenue of ¥789.4B; initiates FY outlook - Seeking Alpha
- 2 months ago - Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion - Benzinga
- 2 months ago - Biogen/ Eisai win EU approval for Alzheimer’s therapy - Seeking Alpha
- 2 months ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 3 months ago - Japanese Stocks Rise With Market Focused on U.S. Trade News - Barron's